{"id":2412,"date":"2018-05-23T00:00:00","date_gmt":"2018-05-23T00:00:00","guid":{"rendered":"http:\/\/centogene.vl22350.dinaserver.com\/2412"},"modified":"2018-05-23T00:00:00","modified_gmt":"2018-05-23T00:00:00","slug":"colaboracion-en-el-desarrollo-de-farmacos-con-orphazyme","status":"publish","type":"post","link":"https:\/\/www.centogene.com\/es\/drug-development-collaboration-with-orphazyme\/","title":{"rendered":"Colaboraci\u00f3n en el desarrollo de f\u00e1rmacos con Orphazyme"},"content":{"rendered":"

CENTOGENE, l\u00edder mundial en la dilucidaci\u00f3n de la gen\u00e9tica de enfermedades raras para pacientes, m\u00e9dicos y socios farmac\u00e9uticos, anunci\u00f3 hoy una colaboraci\u00f3n de desarrollo cl\u00ednico con Orphazyme A\/S (CPH: ORPHA) para mejorar las vidas de los pacientes y las familias que viven con la enfermedad de Gaucher neuronop\u00e1tica, un trastorno de almacenamiento lisosomal raro, hereditario, progresivo y debilitante.<\/p>\n

Seg\u00fan los t\u00e9rminos del acuerdo, CENTOGENE apoya los esfuerzos de ensayos cl\u00ednicos de Orphazyme en India para el uso de la peque\u00f1a mol\u00e9cula arimoclomol para el tratamiento de la enfermedad de Gaucher neuronop\u00e1tica.<\/p>\n

\u201cPoder monitorizar la mejora del tratamiento en un ensayo cl\u00ednico es una capacidad crucial para la industria farmac\u00e9utica actual. Gracias a nuestra amplia experiencia en la identificaci\u00f3n de biomarcadores y el desarrollo de herramientas de diagn\u00f3stico, junto con nuestro profundo conocimiento de las enfermedades raras y nuestro alcance global, estamos en una posici\u00f3n ideal para ser el socio predilecto de Orphazyme y de los desarrolladores de f\u00e1rmacos de todo el mundo\u201d, afirm\u00f3 el Dr. Arndt Rolfs, director ejecutivo y fundador de CENTOGENE.<\/p>\n

CENTOGENE se encarga del procesamiento y an\u00e1lisis de diversos tipos de muestras de los pacientes que participan en el ensayo, incluyendo plasma, l\u00edquido cefalorraqu\u00eddeo y muestras de sangre seca de la CentoCard\u00ae de CENTOGENE. Adem\u00e1s, CENTOGENE ha desarrollado y utiliza el biomarcador m\u00e1s sensible y validado para la enfermedad de Gaucher, la lisoGb1, como herramienta de monitorizaci\u00f3n durante el ensayo.<\/p>\n

Acerca de la enfermedad de Gaucher<\/strong><\/h2>\n

La enfermedad de Gaucher es un trastorno metab\u00f3lico hereditario poco frecuente. Debido a la deficiencia de la enzima glucocerebrosidasa, las mol\u00e9culas de grasa que contienen az\u00facar, llamadas glucol\u00edpidos, se acumulan en los lisosomas celulares. Los s\u00edntomas de la enfermedad de Gaucher incluyen un agrandamiento anormal del h\u00edgado y\/o el bazo (hepatoesplenomegalia), anemia y trombocitopenia, as\u00ed como anomal\u00edas esquel\u00e9ticas. Los s\u00edntomas var\u00edan considerablemente de un paciente a otro, lo que dificulta el desarrollo cl\u00ednico de nuevas terapias en este campo. Los aspectos neurol\u00f3gicos de la enfermedad presentan un futuro incierto en cuanto a la calidad y la esperanza de vida. Aproximadamente entre 10\u00a0000 y 15\u00a0000 personas en Estados Unidos y Europa padecen la enfermedad de Gaucher.<\/p>\n

Acerca de CENTOGENE<\/strong><\/h2>\n

CENTOGENE aprovecha el poder del conocimiento gen\u00e9tico para mejorar la calidad de vida de los pacientes con enfermedades gen\u00e9ticas. Lo logramos gracias al conocimiento generado por nuestros servicios globales de pruebas diagn\u00f3sticas, que incorporan diversidad global, la base de datos patentada de interpretaci\u00f3n gen\u00e9tica humana l\u00edder a nivel mundial, CentoMD\u00ae, y soluciones para compa\u00f1\u00edas farmac\u00e9uticas que desarrollan medicamentos hu\u00e9rfanos que cambian la vida.<\/p>\n

Como una de las empresas de pruebas gen\u00e9ticas m\u00e1s grandes y diversificadas del mundo, CENTOGENE se dedica a transformar la ciencia de la informaci\u00f3n gen\u00e9tica en soluciones y esperanza para los pacientes y sus familias.<\/p>\n

www.centogene.com<\/a> www.centoMD.com<\/a> <\/p>\n

Acerca de Orphazyme A\/S<\/strong><\/h2>\n

Orphazyme es una compa\u00f1\u00eda biofarmac\u00e9utica centrada en ofrecer tratamientos novedosos a pacientes con enfermedades raras potencialmente mortales o debilitantes. Nuestra investigaci\u00f3n se centra en el desarrollo de terapias para enfermedades causadas por el plegamiento incorrecto de prote\u00ednas y la disfunci\u00f3n lisosomal. Arimoclomol, el principal candidato de la compa\u00f1\u00eda, se encuentra en desarrollo cl\u00ednico para cuatro enfermedades hu\u00e9rfanas: enfermedad de Niemann-Pick tipo C, enfermedad de Gaucher, miositis por cuerpos de inclusi\u00f3n espor\u00e1dica y esclerosis lateral amiotr\u00f3fica. La compa\u00f1\u00eda, con sede en Dinamarca, cotiza en el Nasdaq de Copenhague (ORPHA.CO). Para m\u00e1s informaci\u00f3n, visite  www.orphazyme.com<\/a> <\/p>","protected":false},"excerpt":{"rendered":"

CENTOGENE anuncia colaboraci\u00f3n con Orphazyme para el desarrollo de f\u00e1rmacos en la enfermedad de Gaucher neurop\u00e1tica<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2412","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\nDrug development collaboration with Orphazyme | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/es\/colaboracion-en-el-desarrollo-de-farmacos-con-orphazyme\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug development collaboration with Orphazyme | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/es\/colaboracion-en-el-desarrollo-de-farmacos-con-orphazyme\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-23T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"Drug development collaboration with Orphazyme\",\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"},\"wordCount\":493,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\",\"name\":\"Drug development collaboration with Orphazyme | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2018-05-23T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/drug-development-collaboration-with-orphazyme\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Drug development collaboration with Orphazyme\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/es\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Colaboraci\u00f3n en el desarrollo de f\u00e1rmacos con Orphazyme | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/es\/colaboracion-en-el-desarrollo-de-farmacos-con-orphazyme\/","og_locale":"es_ES","og_type":"article","og_title":"Drug development collaboration with Orphazyme | CENTOGENE","og_description":"CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease","og_url":"https:\/\/www.centogene.com\/es\/colaboracion-en-el-desarrollo-de-farmacos-con-orphazyme\/","og_site_name":"CENTOGENE","article_published_time":"2018-05-23T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"Drug development collaboration with Orphazyme","datePublished":"2018-05-23T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"},"wordCount":493,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","url":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/","name":"Colaboraci\u00f3n en el desarrollo de f\u00e1rmacos con Orphazyme | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2018-05-23T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/drug-development-collaboration-with-orphazyme\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"Drug development collaboration with Orphazyme"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Impulsar la medicina de precisi\u00f3n","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"administrador","url":"https:\/\/www.centogene.com\/es\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/comments?post=2412"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/posts\/2412\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/media?parent=2412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/categories?post=2412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/es\/wp-json\/wp\/v2\/tags?post=2412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}